Ekstraordinære indfrielser (CK93) - Totalkredit A/S
Til Nasdaq Copenhagen
Ekstraordinære indfrielser (CK93)
I medfør af kapitalmarkedsloven § 24 offentliggør Totalkredit A/S hermed oplysninger om ekstraordinære indfrielser (CK93) pr. den 3. marts 2023 i vedhæftede fil.
Oplysningerne vil endvidere på sædvanlig måde blive formidlet via Nasdaq Copenhagen. Oplysningerne findes også i excel-format i Nykredits obligationsdatabase på https://www.nykredit.com/en-gb/investor-relations/financial-reporting/prepayments/.
For yderligere informationer om dataformat og -indhold henvises til Nasdaqs hjemmeside.
Spørgsmål kan rettes til head of investor relations Morten Bækmand Nielsen på tlf. 44 55 15 21.
Med venlig hilsen
Totalkredit A/S
Vedhæftede filer
- Ekstraordinære indfrielser - Totalkredit A_S 06-03-2023
- XML_Ekstraordinære indfrielser_Prepayments - Totalkredit A_S 06-03-2023
For at se dette indhold fra ml-eu.globenewswire.com, så skal du give din accept på toppen af denne side.
Information om GlobeNewswire by notified
GlobeNewswire by notifiedGlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Følg pressemeddelelser fra GlobeNewswire by notified
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra GlobeNewswire by notified
Transactions with Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons29.3.2023 22:19:21 CEST | Press release
Company Announcement COPENHAGEN, Denmark; March 29, 2023 –Genmab A/S (Nasdaq:GMAB) -In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document discloses the data of the transactions made in Genmab A/S (Nasdaq: GMAB) by managerial employees and their closely associated persons. The vesting of the restricted stock units granted to Jan G. J. van de Winkel and Anthony Pagano will be subject to forward looking performance criteria and consequently represent the maximum opportunity available if the performance targets have been significantly exceeded. The company’s managerial employees and their closely associated persons have given Genmab A/S power of attorney on their behalf to publish trading in Genmab shares by the company’s managerial employees and their closely associated persons. About Genmab Genmab is an international biotechnology company with a core purpose guiding its unstoppable team to strive towards improving the
Constitution of the Board of Directors in Genmab A/S, Grant of Restricted Stock Units to Management and Employees and Grant of Warrants to Employees in Genmab29.3.2023 22:10:21 CEST | Press release
Company Announcement COPENHAGEN, Denmark; March 29, 2023 –Genmab A/S (Nasdaq:GMAB) Following Genmab A/S’ Annual General Meeting held on March 29, 2023, the Company’s Board of Directors met to constitute itself. Ms. Deirdre P. Connelly was appointed Chair and Ms. Pernille Erenbjerg was appointed Deputy Chair. It was decided to grant90,054restricted stock units to members of managementand employees of the Company and the Company’s subsidiaries and16,276warrants to the employees of the Company andthe Company’s subsidiaries. Each restricted stock unit is awarded cost-free and provides the owner with a right and obligation to receive one share in Genmab A/S of nominally DKK 1. The vesting of the restricted stock units granted to the members of executive management will be subject to forward looking performance criteria and consequently represent the maximum opportunity available if the performance targets have been significantly exceeded. The fair value of each restricted stock unit is equa
US healthcare executive Dr. Ninfa Saunders, DHA, MVA, MSN, FACHE and other Board members to be nominated at general meeting; Chris Lindop not standing for re-election.29.3.2023 22:02:33 CEST | Press release
March 29, 2023 Announcement no. 2 US healthcare executive Dr. Ninfa Saunders, DHA,MVA, MSN, FACHEand other Board members to be nominated at general meeting; Chris Lindop not standing for re-election. COPENHAGEN, DENMARK and BOSTON, MA, USA, March 29, 2023, (GLOBE NEWSWIRE) – The Board of Directors of BioPorto A/S (BioPorto or Company) (CPH:BIOPOR) announces that Chris Lindop, Chairman of the Board of Directors, has for personal reasons decided not to stand for re-election at the upcoming ordinary general meeting. The Board plans to appoint current Vice Chairman, John McDonough, as the new Chairman following the AGM on April 27, 2023. “I am proud to have helped shepherd BioPorto through this period of significant change and opportunity,” said Mr. Lindop. “I am very confident in the Board, Management, and entire team as they commercialize NGAL tests for Acute Kidney Injury (AKI) in Europe and pursue approval of the first authorized AKI biomarker in the US.” The Board also announces that
Inventiva reports its 2022 full-year results29.3.2023 22:00:00 CEST | Press release
Cash and cash equivalents at €86.7 million and short term deposits at €1 million as of December 31, 2022 compared to €86.6 million and €8.8 million, respectively as of December 31, 2021 Inventiva entered into a license and collaboration agreement with Sino Biopharm a leading Chinese pharmaceutical group, through CTTQ, to develop, manufacture and commercialize lanifibranor in Greater China Under this agreement with Sino Biopharm, Inventiva received a €12.8 million¹ upfront payment Inventiva received the first tranche of €25 million under its credit facility with the European Investment Bank (EIB) Screening of the first patients in LEGEND, a Phase IIa combination trial with lanifibranor and empagliflozin in patients with NASH and T2D Secured a new patent expanding the IP protection of lanifibranor in the U.S. In January 2023, Inventiva announced changes to NATiV3, a Phase III trial with lanifibranor in patients with NASH, that are expected to be beneficial to the clinical program Daix (F
Nova Klúbburinn hf.: Niðurstöður aðalfundar þann 29. mars 202329.3.2023 21:54:28 CEST | Press release
Aðalfundur Nova Klúbbsins hf. var haldinn í dag, miðvikudaginn, 29. mars 2023. Þetta var fyrsti aðalfundur í skráðu félagi sem eingöngu var stýrt af konum en Hrund Rudolfsdóttir flutti skýrslu stjórnar, Margrét Tryggvadóttir skemmtana- & forstjóri fór yfir árið, Svanhildur Magnúsdóttir var fundarstjóri og ritari fundar var Ásta Guðjónsdóttir. Í stjórn félagsins voru kjörnir eftirfarandi einstaklingar: Hrund Rudolfsdóttir Jón Óttar Birgisson Jóhannes Þorsteinsson Magnús Árnason Sigríður Olgeirsdóttir Jóhannes, Sigríður og Magnús koma inn í stjórnina í stað Hugh Short, Kevin Payne og Tinu Pidgeon. Stjórn hefur skipt með sér verkum og var Sigríður Olgeirsdóttir kjörinn formaður stjórnar. Jóhannes Þorsteinsson starfar í dag sem yfirmaður fjárstýringar T-Mobile í Bandaríkjunum, þar sem hann ber ábyrgð á allri fjármögnun fyrirtækisins. T-Mobile er leiðandi fyrirtæki á fjarskiptamarkaði í Ameríku. Sigríður Olgeirsdóttir er reyndur stjórnandi í hugbúnaðar- og hátæknigeiranum. Magnús er sjálfst